Case Study of Biodefense R&D Coordination and Implementation

10:10 AM - 11:55 AM

Room C

How do you prioritize biodefense R&D resources and investments across the Federal Government? What strategies can be used to maximize impact while reducing costs? Explore how the Biological Defense Research & Development community informs and implements biological defense strategies across disparate branches of government. Hear viewpoints on strategic planning, coordination, and implementation from laboratories to agencies.


Paula Bryant,

National Institute of Allergy and Infectious Diseases, NIH:

will discuss NIAID’s role--specifically the Office of Biodefense, Research Resources, and Translational Research--in medical countermeasure development for biodefense and emerging infectious diseases, to include the mechanisms used to access and assess expertise, innovations, and platform technologies in the private sector; what type of services we have available for researchers who need help translating their discoveries into products; and how NIAID uses all of the above to develop medical countermeasures for the known threat versus responding to an emerging infectious disease or outbreak.

[presenter materials]

George Korch,

National Biodefense Analysis and Countermeasures Center, DHS:

will discuss how NBACC and other laboratories at the Fort Detrick represent locations where Federal partnerships are occurring to coordinate biodefense S&T.

Richard Schoske,

Defense Threat Reduction Agency (DTRA):

will provide a basic overview of DTRA’s role in S&T for biodefense and in addressing the future threats.

[presenter materials]

Gerald Epstein,


Gerald Epstein will provide a historical review of White House biodefense strategies and how they involve science and technology.

Discussion Questions:

  • How well do we plan for long-range needs? How do we address long- based threats? How do you maintain core capabilities while rapidly developing new capabilities to address future needs?
  • What are the opportunities that might be available to entities outside of the federal structure to assist in filling strategic gaps?
  • Does the biodefense community approach that you describe translate well into other domains?
  • Is there a need for a national strategy document for every type of S&T endeavor in which the USG would choose to invest, and how might I be able to influence that document?
  • What are future opportunities for national coordination on strategic planning across government? with industry?